Paul Scherrer Institute selects RayStation

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

STOCKHOLM, Oct. 2, 2023 /PRNewswire/ -- Renowned worldwide for its treatment of cancers with proton therapy, PSI has selected RayStation as the treatment planning system for its clinical operations. PSI is equipped with three gantries and a fixed horizontal beam line room for ocular treatments. Two of the gantries, of which one is in-house developed, operate clinically while the third is dedicated to research.

Metadata
Provider: 
PR NewswirePR Newswire
Retrieved on: 
Monday, October 2, 2023
Information
Tags: 
PSI, RaySearch Laboratories, Paul Scherrer Institute, Indiana University Health Proton Therapy Center, Cancer, Partnership, Research, Proton therapy, Medical imaging
Geotags: 
SWEDEN
Stock Symbol: 
Bloomberg:RAYB@SS
ISIN:SE0000135485
RICS:RAYB.ST
Stockholm:RAYB
Summary
Key Points: 
  • STOCKHOLM, Oct. 2, 2023 /PRNewswire/ -- Renowned worldwide for its treatment of cancers with proton therapy, PSI has selected RayStation as the treatment planning system for its clinical operations.
  • Two of the gantries, of which one is in-house developed, operate clinically while the third is dedicated to research.
  • Alongside the procurement of RayStation, RaySearch and PSI have the intent of engaging in a collaborative research initiative.
  • Damien C. Weber, Chairman of the proton Therapy Center, Paul Scherrer Institute, says: "By combining proton therapy with advanced treatment planning system as proposed by RaySearch, we can push the boundaries of optimal cancer care.


Paul Scherrer Institute selects RayStation

RaySearch Laboratories AB (publ) is pleased to announce that the Paul Scherrer Institute (PSI) in Switzerland has placed an order for the treatment planning system RayStation®*.

STOCKHOLM, Oct. 2, 2023 /PRNewswire/ -- Renowned worldwide for its treatment of cancers with proton therapy, PSI has selected RayStation as the treatment planning system for its clinical operations. PSI is equipped with three gantries and a fixed horizontal beam line room for ocular treatments. Two of the gantries, of which one is in-house developed, operate clinically while the third is dedicated to research.

Alongside the procurement of RayStation, RaySearch and PSI have the intent of engaging in a collaborative research initiative. This partnership will focus on a range of strategic areas, including online adaptive proton therapy.

Damien C. Weber, Chairman of the proton Therapy Center, Paul Scherrer Institute, says: "By combining proton therapy with advanced treatment planning system as proposed by RaySearch, we can push the boundaries of optimal cancer care. We look forward to collaborating with one of the leading developers of treatment planning systems to share our expertise in proton therapy and advance research in various areas, including but not limited to treatment plan adaptation."

Johan Löf, founder and CEO, RaySearch, says: "PSI is an exceptional place to treat cancer, and I am proud to welcome them as customers. It is also very exciting to engage in several research projects together with a partner with such strong research capabilities. This will be beneficial for the next generation of RayStation as well as an important step in fulfilling our vision of a world where cancer is conquered."

CONTACT:

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
[email protected]

The following files are available for download:

Cision View original content:https://www.prnewswire.com/news-releases/paul-scherrer-institute-selects-raystation-301944214.html

SOURCE RaySearch Laboratories

Copyright: 
2023 PR Newswire. All Rights Reserved.